Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objectives: Evaluate the relationship between naloxone dose (initial and cumulative) and opioid toxicity reversal and adverse events in undifferentiated and presumed fentanyl/ultra-potent opioid overdoses. Methods: We searched Embase, MEDLINE, Cochrane Central Register of Controlled Trials, DARE, CINAHL, Science Citation Index, reference lists, toxicology websites, and conference proceedings (1972 to 2018). We included interventional, observational, and case studies/series reporting on naloxone dose and opioid toxicity reversal or adverse events in people >12 years old. Results: A total of 174 studies (110 case reports/series, 57 observational, 7 interventional) with 26,660 subjects (median age 35 years; 74% male). Heterogeneity precluded meta-analysis. Where reported, we abstracted naloxone dose and proportion of patients with toxicity reversal. Among patients with presumed exposure to fentanyl/ultra-potent opioids, 56.9% (617/1,085) responded to an initial naloxone dose ≤0.4 mg compared with 80.2% (170/212) of heroin users, and 30.4% (7/23) responded to an initial naloxone dose >0.4 mg compared with 59.1% (1,434/2,428) of heroin users. Among patients who responded, median cumulative naloxone doses were higher for presumed fentanyl/ultra-potent opioids than heroin overdoses in North America, both before 2015 (fentanyl/ultra-potent opioids: 1.8 mg [interquartile interval {IQI}, 1.0, 4.0]; heroin: 0.8 mg [IQI, 0.4, 0.8]) and after 2015 (fentanyl/ultra-potent opioids: 3.4 mg [IQI, 3.0, 4.1]); heroin: 2 mg [IQI, 1.4, 2.0]). Where adverse events were reported, 11% (490/4,414) of subjects experienced withdrawal. Variable reporting, heterogeneity and poor-quality studies limit conclusions. Conclusions: Practitioners have used higher initial doses, and in some cases higher cumulative naloxone doses to reverse toxicity due to presumed fentanyl/ultra-potent opioid exposure compared with other opioids. High-quality comparative naloxone dosing studies assessing effectiveness and safety are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-communicable diseases must have greater priority, says WHO
Zarocostas, J. (2009) · BMJ · doi:10.1136/bmj.b2857 · Cited by 517
Amlani, A., McKee, G., Khamis, N., Raghukumar, G., Tsang, E., & Buxton, J. A. (2015) · Harm Reduction Journal · doi:10.1186/s12954-015-0088-4 · Cited by 134
Self-citation
Cited by
Shover, C. L., Falasinnu, T. O., Dwyer, C. L., Santos, N. B., Cunningham, N. J., Freedman, R. B., Vest, N. A., & Humphreys, K. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108314 · Cited by 162
“Increasing the standard dose of naloxone is also warranted because overdoses involving synthetic opioids like fentanyl and fentanyl analogues often require more naloxone to reverse (Frank and Pollack, 2017; Moe et al., 2020).”
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
A call for compassionate opioid overdose response
Russell, E., Hawk, M., Neale, J., Bennett, A. S., Davis, C., Hill, L. G., Winograd, R., Kestner, L., Lieberman, A., Bell, A., et al. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104587 · Cited by 28
Alhosan, N., Cavallo, D., Santiago, M., Kelly, E., & Henderson, G. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17376 · Cited by 23
“There have been numerous reports of more naloxone, in the form of multiple or higher doses, being required to reverse over-doses involving fentanyls and nitazenes compared with heroin over-doses (Amaducci et al., 2023; Irvine et al., 2022; Moe et al., 2020).”
Alhosan, N., Cavallo, D., Santiago, M., Kelly, E., & Henderson, G. (2024) · doi:10.1101/2024.06.04.597322 · Cited by 1
Metadata
- Authors
- Moe, J., Godwin, J., Purssell, R., O'Sullivan, F., Hau, J. P., Purssell, E., Curran, J., Doyle-Waters, M. M., Brasher, P. M. A., Buxton, J. A., & Hohl, C. M.
- Venue
- CJEM
- Published
- 2020-01-20
- Volume
- 22
- Issue
- 2
- Pages
- 178-186
- ISSN
- 1481-8035 (ISSN-L)
- 1481-8043
- OpenAlex
- W3002632925
- Cited by
- 45
- References
- 2
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.